Table 1.
The non-[18F]FDG PET criteria main characteristics and description.
| Reference | Year | Radiotracer | Criteria | Description |
|---|---|---|---|---|
| Fanti et al. [8] | 2017 | PSMA-ligand | EANM criteria | All “anomalous” findings suggestive of recurrent PCa were noticed and categorized as “pathologic” unless another explanation could be hypothesized. |
| Rowe et al. [9] | 2018 | PSMA-ligand | PSMA-RADS | 5-point scale framework reflecting the level of confidence in interpreting PSMA-PET imaging in PCa. |
| Eiber et al. [10] | 2019 | PSMA-ligand | PROMISE (miTNM) | Standardized reporting framework based on miTNM system for PSMA-ligand PET/CT or PET/MRI imaging in PCa. |
| Ceci et al. [11] | 2021 | PSMA-ligand | E-PSMA | The E-PSMA standardized reporting guidelinesprovide consensus statements to develop a structuredreport for PSMA-PET in PCa. |
| Adnan et al. [12] | 2021 | PSMA/FDG | Pro-PET | An integrated dual tracer PET/CT (PSMA and FDG) image scoring system for mCRPCa patients referred to [177Lu]Lu-PSMA therapy. |
| Emmett et al. [13] | 2022 | PSMA-ligand | PRIMARY | A 5-level score for the diagnosis of clinically significant PCa. |
| Fanti et al. [14] | 2020 | PSMA-ligand | PSMA PET Progression (PPP) | PSMA-driven response evaluation criteria in patients with metastatic PCa. |
| Grafita et al. [15] | 2022 | PSMA-ligand | RECIP 1.0 | PSMA-driven response evaluation criteria in mCRPCa patients who underwent [177Lu]Lu-PSMA therapy. |
| Krenning et al. [16] * | 1999 | SSTR-ligand | Krenning | Visual interpretation criteria for evaluating NETs patients’ eligibility for [177Lu]Lu DOTA therapy. |
| Werner et al. [17] | 2018 | SSTR-ligand | SSTR-RADS | 5-point scale framework reflecting the level of confidence of interpreting SSTR-PET imaging in NET assessing the eligibility to [177Lu]Lu-DOTA therapy. |
| Chan et al. [18] | 2017 | SSTR/FDG | NETPET | An integrated dual tracer PET/CT (SSTR and FDG) image scoring system for NET patients. |
| Zwirtz et al. [19] | 2021 | SSTR-ligand | MORE; ZP | Response evaluation criteria in NETs patients who underwent [177Lu]Lu-DOTA therapy. |
| Kairemo et al. [20] | 2019 | [18F]NaF | NAFCIST | Response evaluation criteria for high-risk osteosarcoma patients who underwent [223Ra]Cl2 therapy. |
| García Vicente et al. [21] | 2020 | [18F]Fluorocholine | FuMeGa | Visual interpretation criteria for post-surgery evaluation of HGG patients |
* Adapted from [111In]Pentetreotide imaging to SSTR PET-imaging. Abbreviations: PSMA, prostate-specific membrane antigen; EANM, European Association of Nuclear Medicine; PCa, prostate cancer; RADS, Reporting and Data Systems; PET, positron emission tomography; mi, molecular imaging; CT, computed tomography; MRI, magnetic resonance imaging; FDG, fluorodeoxyglucose; mCRPCa, metastatic castration-resistant PCa; SSTR, somatostatin receptor; NET, neuroendocrine tumor; HGG, high-grade glioma.